Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis

References

• Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942–955.
   PubMed Web of Science ®Google Scholar
• Bucchia M, Ramirez A, Parente V, et al. Therapeutic development in amyotrophic lateral sclerosis. Clin Ther. 2015;37(3):668–680.
   PubMed Web of Science ®Google Scholar
• Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391–397.
   PubMed Web of Science ®Google Scholar
• Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA. 2015;313(14):1451–1462.
   PubMed Web of Science ®Google Scholar
• Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4(5):399–415.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Pecoraro R, Arnao V, et al. Developing drug strategies for the neuroprotective treatment of acute ischemic stroke. Expert Rev Neurother. 2015;15(11):1271–1284.
   PubMed Web of Science ®Google Scholar
• Kim C, Lee HC, Sung -J-J. Amyotrophic lateral sclerosis - cell based therapy and novel therapeutic development. Exp Neurobiol. 2014;23(3):207.
   PubMedGoogle Scholar
• Chen KS, Sakowski SA, Feldman EL. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. Ann Neurol. 2016;79(3):342–353.
   PubMed Web of Science ®Google Scholar
• Moujalled D, White AR. Advances in the development of disease-modifying treatments for amyotrophic lateral sclerosis. CNS Drugs. 2016;30(3):227–243.
   PubMed Web of Science ®Google Scholar
• Moura MC, Novaes MR, Zago YS, et al. Efficacy of stem cell therapy in amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Clin Med Res. 2016;8(4):317–324.
   PubMedGoogle Scholar
• Kwiecinski H, Janik P, Jamrozik Z, et al. [The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials]. Neurol Neurochir Pol. 2001;35(1 Suppl):101–106.
   PubMedGoogle Scholar
• Crow JP, Calingasan NY, Chen J, et al. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol. 2005;58(2):258–265.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059–1067.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7–8):610–617.
   PubMed Web of Science ®Google Scholar
• Park SB, Vucic S, Cheah BC, et al. Flecainide in amyotrophic lateral sclerosis as a neuroprotective strategy (FANS): a randomized placebo-controlled trial. EBioMedicine. 2015;2:1916–1922.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Misawa S, Kimura H, et al. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: efficacy and safety of sodium channel blocker phase II trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5–6):353–358.
   PubMed Web of Science ®Google Scholar
• Weiss MD, Macklin EA, Simmons Z, et al. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86:1474–1481.
   PubMed Web of Science ®Google Scholar
• Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20(3):589–602.
   PubMed Web of Science ®Google Scholar
• Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26(4):438–458.
   PubMed Web of Science ®Google Scholar
• Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol. 1990;28(1):3–8.
   PubMed Web of Science ®Google Scholar
• Kwak S, Hideyama T, Yamashita T, et al. AMPA receptor-mediated neuronal death in sporadic ALS. Neuropathology. 2010;30(2):182–188.
   PubMed Web of Science ®Google Scholar
• Lu YM, Yin HZ, Chiang J, et al. Ca(2+)-permeable AMPA/kainate and NMDA channels: high rate of Ca2+ influx underlies potent induction of injury. J Neurosci. 1996;16(17):5457–5465.
   PubMed Web of Science ®Google Scholar
• Sasabe J, Chiba T, Yamada M, et al. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J. 2007;26(18):4149–4159.
   PubMed Web of Science ®Google Scholar
• Prehn JH, Lippert K, Krieglstein J. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury? Eur J Pharmacol. 1995;292(2):179–189.
   PubMed Web of Science ®Google Scholar
• Petri S, Krampfl K, Hashemi F, et al. Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J Neuropathol Exp Neurol. 2003;62(10):1041–1051.
   PubMed Web of Science ®Google Scholar
• Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol. 1993;86(1):55–64.
   PubMed Web of Science ®Google Scholar
• Ferrer I, Tunon T, Serrano MT, et al. Calbindin D-28k and parvalbumin immunoreactivity in the frontal cortex in patients with frontal lobe dementia of non-Alzheimer type associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1993;56(3):257–261.
   PubMed Web of Science ®Google Scholar
• Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2012;13(3):245–250.
   PubMed Web of Science ®Google Scholar
• Maekawa S, Al-Sarraj S, Kibble M, et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain. 2004;127(Pt 6):1237–1251.
   PubMed Web of Science ®Google Scholar
• Petri S, Kollewe K, Grothe C, et al. GABA(A)-receptor mRNA expression in the prefrontal and temporal cortex of ALS patients. J Neurol Sci. 2006;250(1–2):124–132.
   PubMed Web of Science ®Google Scholar
• Stephens B, Guiloff RJ, Navarrete R, et al. Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease. A morphometric study. J Neurol Sci. 2006;244(1–2):41–58.
   PubMed Web of Science ®Google Scholar
• Lorenzo LE, Barbe A, Portalier P, et al. Differential expression of GABAA and glycine receptors in ALS-resistant vs. ALS-vulnerable motoneurons: possible implications for selective vulnerability of motoneurons. Eur J Neurosci. 2006;23(12):3161–3170.
   PubMed Web of Science ®Google Scholar
• Turner MR, Osei-Lah AD, Hammers A, et al. Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS. J Neurol Neurosurg Psychiatry. 2005;76(9):1279–1285.
   PubMed Web of Science ®Google Scholar
• Wittstock M, Wolters A, Benecke R. Transcallosal inhibition in amyotrophic lateral sclerosis. Clin Neurophysiol. 2007;118(2):301–307.
   PubMed Web of Science ®Google Scholar
• Jiang M, Schuster JE, Fu R, et al. Progressive changes in synaptic inputs to motoneurons in adult sacral spinal cord of a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2009;29(48):15031–15038.
   PubMed Web of Science ®Google Scholar
• Raynor EM, Shefner JM. Recurrent inhibition is decreased in patients with amyotrophic lateral sclerosis. Neurology. 1994;44(11):2148–2153.
   PubMed Web of Science ®Google Scholar
• Lloyd CM, Richardson MP, Brooks DJ, et al. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain. 2000;123(Pt 11):2289–2296.
   PubMed Web of Science ®Google Scholar
• Turner MR, Hammers A, Al-Chalabi A, et al. Distinct cerebral lesions in sporadic and ‘D90A’ SOD1 ALS: studies with [11C]flumazenil PET. Brain. 2005;128(Pt 6):1323–1329.
   PubMed Web of Science ®Google Scholar
• Douaud G, Filippini N, Knight S, et al. Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain. 2011;134(Pt 12):3470–3479.
   PubMed Web of Science ®Google Scholar
• Wicks P, Turner MR, Abrahams S, et al. Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: an (11C)-flumazenil PET study. Amyotroph Lateral Scler. 2008;9(1):43–49.
   PubMed Web of Science ®Google Scholar
• Zanette G, Tamburin S, Manganotti P, et al. Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(12):1723–1728.
   PubMed Web of Science ®Google Scholar
• Zanette G, Tamburin S, Manganotti P, et al. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol. 2002;113(11):1688–1697.
   PubMed Web of Science ®Google Scholar
• Vucic S, Howells J, Trevillion L, et al. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve. 2006;33(4):477–486.
   PubMed Web of Science ®Google Scholar
• Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006;129(Pt 9):2436–2446.
   PubMed Web of Science ®Google Scholar
• Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015;14(5):478–484.
   PubMed Web of Science ®Google Scholar
• Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(Pt 6):1540–1550.
   PubMed Web of Science ®Google Scholar
• Bostock H, Sharief MK, Reid G, et al. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain. 1995;118(Pt 1):217–225.
   PubMed Web of Science ®Google Scholar
• Kanai K, Kuwabara S, Misawa S, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain. 2006;129(Pt 4):953–962.
   PubMed Web of Science ®Google Scholar
• Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006;117(7):1458–1466.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Vucic S, Krishnan AV, et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942–1199.
   PubMed Web of Science ®Google Scholar
• Nakata M, Kuwabara S, Kanai K, et al. Distal excitability changes in motor axons in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006;117(7):1444–1448.
   PubMed Web of Science ®Google Scholar
• Noto Y, Kanai K, Misawa S, et al. Distal motor axonal dysfunction in amyotrophic lateral sclerosis. J Neurol Sci. 2011;302(1–2):58–62.
   PubMed Web of Science ®Google Scholar
• Geevasinga N, Menon P, Howells J, et al. Axonal ion channel dysfunction in c9orf72 familial amyotrophic lateral sclerosis. JAMA Neurol. 2015;72(1):49–57.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Misawa S, Arai K, et al. Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: an immunohistochemical study. Exp Neurol. 2011;232(2):149–153.
   PubMed Web of Science ®Google Scholar
• Nutini M, Spalloni A, Florenzano F, et al. Increased expression of the beta3 subunit of voltage-gated Na+ channels in the spinal cord of the SOD1G93A mouse. Mol Cell Neurosci. 2011;47(2):108–118.
   PubMed Web of Science ®Google Scholar
• Eisen A, Kim S, Pant B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? Muscle Nerve. 1992;15(2):219–224.
   PubMed Web of Science ®Google Scholar
• Vucic S, Ziemann U, Eisen A, et al. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry. 2013;84(10):1161–1170.
   PubMed Web of Science ®Google Scholar
• Sekiguchi T, Kanouchi T, Shibuya K, et al. Spreading of amyotrophic lateral sclerosis lesions–multifocal hits and local propagation? J Neurol Neurosurg Psychiatry. 2014;85(1):85–91.
   PubMed Web of Science ®Google Scholar
• Ayers JI, Fromholt SE, O’Neal VM, et al. Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Acta Neuropathol. 2016;131(1):103–114.
   PubMed Web of Science ®Google Scholar
• Ravits J. Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exp Neurol. 2014;262 Pt B:121–126.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:Cd001447.
   PubMed Web of Science ®Google Scholar
• Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci. 2000;12(10):3567–3574.
   PubMed Web of Science ®Google Scholar
• Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch. 1991;419(6):603–609.
   PubMed Web of Science ®Google Scholar
• Wang Y-J, Lin M-W, Lin -A-A, et al. Riluzole-induced block of voltage-gated Na+ current and activation of BKCa channels in cultured differentiated human skeletal muscle cells. Life Sci. 2008;82(1–2):11–20.
   PubMed Web of Science ®Google Scholar
• Lamanauskas N, Nistri A. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008;27(10):2501–2514.
   PubMed Web of Science ®Google Scholar
• Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci. 2005;233(1–2):3–13.
   PubMed Web of Science ®Google Scholar
• Stys PK. Sodium channel blockers as neuroprotectants in neuroinflammatory disease: a double-edged sword. Ann Neurol. 2007;62(1):3–5.
   PubMed Web of Science ®Google Scholar
• Vucic S, Lin CS, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. 2013;136(Pt 5):1361–1370.
   PubMed Web of Science ®Google Scholar
• Krishnan AV, Lin CS, Park SB, et al. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol. 2009;89(3):288–313.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Lin CS, Park SB, et al. Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012;123(12):2460–2467.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. N Engl J Med. 1994;330(9):585–591.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole study group II. Lancet. 1996;347(9013):1425–1431.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(5):609–615.
   PubMed Web of Science ®Google Scholar
• Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet. 1988;1(8575–8576):9–11.
   PubMed Web of Science ®Google Scholar
• Kwieciński H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand. 1992;86(4):371–375.
   PubMed Web of Science ®Google Scholar
• Kanai K, Shibuya K, Sato Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734–738.
   PubMed Web of Science ®Google Scholar
• Aliot E, Capucci A, Crijns HJ, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011;13(2):161–173.
   PubMed Web of Science ®Google Scholar
• Swash M, De Carvalho M. The neurophysiological index in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):108–110.
   PubMed Web of Science ®Google Scholar
• Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68(15):1197–1204.
   PubMed Web of Science ®Google Scholar
• Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol. 2009;156(8):1185–1195.
   PubMed Web of Science ®Google Scholar
• Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1–11.
   PubMed Web of Science ®Google Scholar
• Katayama Y, Maeda K, Iizuka T, et al. Accumulation of oxidative stress around the stroke-like lesions of MELAS patients. Mitochondrion. 2009;9(5):306–313.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Kawahara KI, Uchikado H, et al. Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. Exp Ther Med. 2011;2(5):771–775.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Takeshige N, Miura N, et al. Beyond free radical scavenging: beneficial effects of edaravone (Radicut) in various diseases (Review). Exp Ther Med. 2012;3(1):3–8.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Yuki S, Egawa M, et al. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268(3):1597–1604.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yuki S, Watanabe T, et al. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res. 1997;762(1–2):240–242.
   PubMed Web of Science ®Google Scholar
• Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol. 1998;30(4):575–578.
   PubMedGoogle Scholar
• Beal MF, Ferrante RJ, Browne SE, et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42(4):644–654.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Shinobu LA, Schulz JB, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol. 1997;42(3):326–334.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS One. 2015;10(10):e0140316.
   PubMed Web of Science ®Google Scholar
• Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med. 2012;4(145):145ra104.
   PubMed Web of Science ®Google Scholar
• Bilican B, Serio A, Barmada SJ, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012;109(15):5803–5808.
   PubMed Web of Science ®Google Scholar
• Mitne-Neto M, Machado-Costa M, Marchetto MC, et al. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum Mol Genet. 2011;20(18):3642–3652.
   PubMed Web of Science ®Google Scholar
• Yao XL, Ye CH, Liu Q, et al. Motoneuron differentiation of induced pluripotent stem cells from SOD1G93A mice. PLoS One. 2013;8(5):e64720.
   Web of Science ®Google Scholar
• Liu X, Chen J, Liu W, et al. The fused in sarcoma protein forms cytoplasmic aggregates in motor neurons derived from integration-free induced pluripotent stem cells generated from a patient with familial amyotrophic lateral sclerosis carrying the FUS-P525L mutation. Neurogenetics. 2015;16(3):223–231.
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321(5893):1218–1221.
   PubMed Web of Science ®Google Scholar
• Almeida S, Gascon E, Tran H, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013;126(3):385–399.
   PubMed Web of Science ®Google Scholar